2025
Decongestion in heart failure: medical and device therapies
Cox Z, Damman K, Testani J. Decongestion in heart failure: medical and device therapies. Nature Reviews Cardiology 2025, 1-17. PMID: 40295876, DOI: 10.1038/s41569-025-01152-z.Peer-Reviewed Original ResearchHeart failure symptomsHeart failureDevice therapyFailure symptomsPersistent heart failure symptomsDesign of clinical trialsImplementing novel therapiesHeart failure outcomesMagnitude of benefitImprove decongestionPrimary therapyLoop diureticsResidual congestionNovel therapiesAdverse outcomesClinical trialsTherapyMedical strategiesPredominant causeFailure outcomesHospital readmissionHospitalTargeting congestionDecongestionHeart
2024
High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series
Epperla N, Zayac A, Landsburg D, Bock A, Nowakowski G, Ayers E, Girton M, Hu M, Beckman A, Li S, Medeiros L, Chang J, Kurt H, Sandoval-Sus J, Ansari-Lari M, Kothari S, Kress A, Xu M, Torka P, Sundaram S, Smith S, Naresh K, Karimi Y, Bond D, Evens A, Naik S, Kamdar M, Haverkos B, Karmali R, Farooq U, Vose J, Rubinstein P, Chaudhry A, Olszewski A. High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series. Blood Advances 2024, 8: 5355-5364. PMID: 39189932, PMCID: PMC11568788, DOI: 10.1182/bloodadvances.2024013791.Peer-Reviewed Original ResearchBaseline CNS involvementCentral nervous system recurrenceHigh-grade B-cell lymphomaCentral nervous systemB-cell lymphomaCNS involvementCNS recurrenceIncidence of CNS recurrenceRisk of CNS recurrenceCentral nervous system involvementMulti-institutional seriesNon-GCB subtypeBone marrow involvementMulticenter retrospective studyCNS-IPIRisk factor analysisMarrow involvementMYC rearrangementNon-GCBPrimary therapyCD5 expressionAutologous transplantationSurvival outcomesNo significant differenceNOS patientsNovel physiologic predictors of positive airway pressure effectiveness (NICEPAP) study: rationale, design and methods
Anwar A, Byrne S, Sharma A, Sands S, Wellman A, Redeker N, Yaggi H, Zinchuk A. Novel physiologic predictors of positive airway pressure effectiveness (NICEPAP) study: rationale, design and methods. Sleep And Breathing 2024, 28: 2005-2015. PMID: 38995327, DOI: 10.1007/s11325-024-03099-w.Peer-Reviewed Original ResearchObstructive sleep apneaPositive airway pressure effectObstructive sleep apnea traitsCPAP effectsCPAP adherencePrimary outcomePurposeContinuous positive airway pressureFunctional Outcomes of Sleep QuestionnaireEffects of CPAPPositive airway pressureAcademic sleep centerObservational cohort studyPrecision medicine approachCPAP dataCPAP efficacyBaseline polysomnographySleep apneaPrimary therapyAirway pressureSleep centerArousal thresholdPatient-centered outcomesPharyngeal collapseSleep qualityCPAP
2023
Effect of Torsemide Versus Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial
Greene S, Velazquez E, Anstrom K, Clare R, DeWald T, Psotka M, Ambrosy A, Stevens G, Rommel J, Alexy T, Ketema F, Kim D, Desvigne-Nickens P, Pitt B, Eisenstein E, Mentz R, Investigators O. Effect of Torsemide Versus Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial. Circulation 2023, 148: 124-134. PMID: 37212600, PMCID: PMC10524905, DOI: 10.1161/circulationaha.123.064842.Peer-Reviewed Original ResearchConceptsPatient Health Questionnaire-2Prespecified secondary end pointsQuality of lifeEffects of torsemideSecondary end pointsHeart failurePatient-reported outcomesKansas City Cardiomyopathy Questionnaire clinical summary scoreNew York Heart Association classPatient Health Questionnaire-2 scoreEnd pointQuestionnaire-2Loop diuretic agentsLoop diuretic useProportion of patientsBaseline health statusClinical summary scoreEjection fraction phenotypeSignificant differencesDiuretic strategyTorsemide groupCause hospitalizationCause mortalityDiuretic usePrimary therapyTreatment of Vestibular Schwannomas Refractory to Primary Therapy: Considerations for Subsequent Microsurgery and Radiation
Cottrell J, Kay-Rivest E, Rotman L, Friedmann D, Jethanamest D, McMenomey S, Pacione D, Sen C, Golfinos J, Roland T. Treatment of Vestibular Schwannomas Refractory to Primary Therapy: Considerations for Subsequent Microsurgery and Radiation. Journal Of Neurological Surgery Part B Skull Base 2023, 84: s1-s344. DOI: 10.1055/s-0043-1762141.Peer-Reviewed Original Research
2020
Oligometastatic Disease and Local Therapies: A Medical Oncology Perspective.
Hafez N, Gettinger S. Oligometastatic Disease and Local Therapies: A Medical Oncology Perspective. The Cancer Journal 2020, 26: 144-148. PMID: 32205539, DOI: 10.1097/ppo.0000000000000439.Peer-Reviewed Original ResearchConceptsAggressive local therapySubset of patientsLocal therapyOligometastatic diseaseCancer patientsNon-small cell lung cancer patientsOligometastatic colorectal cancer (CRC) patientsCell lung cancer patientsLong-term disease remissionStereotactic body radiation therapyLimited nodal involvementMedical oncology perspectiveDefinitive local therapyColorectal cancer patientsSolid tumor patientsLung cancer patientsSolid tumor malignanciesBody radiation therapyDisease remissionOligometastatic statePrimary therapyNodal involvementOverall survivalSystemic therapyMetastatic sites
2019
Retroperitoneal Lymph Node Dissection as Primary Treatment for Men With Testicular Seminoma: Utilization and Survival Analysis Using the National Cancer Data Base, 2004-2014
Tabakin AL, Shinder BM, Kim S, Rivera-Nunez Z, Polotti CF, Modi PK, Sterling JA, Farber NJ, Radadia KD, Parikh RR, Kim IY, Saraiya B, Mayer TM, Singer EA, Jang TL. Retroperitoneal Lymph Node Dissection as Primary Treatment for Men With Testicular Seminoma: Utilization and Survival Analysis Using the National Cancer Data Base, 2004-2014. Clinical Genitourinary Cancer 2019, 18: e194-e201. PMID: 31818649, DOI: 10.1016/j.clgc.2019.10.018.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultFollow-Up StudiesHumansKaplan-Meier EstimateLymph Node ExcisionLymph NodesLymphatic MetastasisMaleMiddle AgedNeoplasm StagingOrchiectomyRegistriesRetroperitoneal SpaceRetrospective StudiesSeminomaSurvival RateTesticular NeoplasmsTestisTreatment OutcomeUnited StatesYoung AdultConceptsRetroperitoneal lymph node dissectionPrimary retroperitoneal lymph node dissectionLymph node dissectionOverall survivalTesticular seminomaNode dissectionRole of RPLNDTesticular nonseminomatous germ cell tumorsNational Cancer Data BaseNonseminomatous germ cell tumorsPrimary testicular cancerFive-year OSFirst-line treatmentKaplan-Meier methodOngoing prospective trialsGerm cell tumorsIIB diseaseOS ratesPrimary chemotherapyPrimary therapyProspective trialFinal cohortStage IIATumor histologyClinical stageEstimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
Burstein H, Curigliano G, Loibl S, Dubsky P, Gnant M, Poortmans P, Colleoni M, Denkert C, Piccart-Gebhart M, Regan M, Senn H, Winer E, Thurlimann B, 2019 M. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Annals Of Oncology 2019, 30: 1541-1557. PMID: 31373601, DOI: 10.1093/annonc/mdz235.Peer-Reviewed Original ResearchConceptsEarly-stage breast cancerBreast cancerBreast cancer histologyClinical benefitCancer histologySt. Gallen Consensus ConferenceEarly breast cancerInternational consensus guidelinesBenefits of therapyBreast cancer recurrenceSubstantial new evidenceMagnitude of benefitAdjuvant therapyLack of evidencePrimary therapyOverall survivalSystemic therapyHealthy womenConsensus guidelinesCancer recurrenceAppropriate treatmentClinical studiesIndividual patientsPatient participationConsensus conference
2018
Correction to: De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn H, Thürlimann B, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang C, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B. Correction to: De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Annals Of Oncology 2018, 29: 2153. PMID: 29733336, PMCID: PMC6887963, DOI: 10.1093/annonc/mdx806.Peer-Reviewed Original ResearchGastrointestinal and Extra-Intestinal Manifestations of IgG4–Related Disease
Miyabe K, Zen Y, Cornell LD, Rajagopalan G, Chowdhary VR, Roberts LR, Chari ST. Gastrointestinal and Extra-Intestinal Manifestations of IgG4–Related Disease. Gastroenterology 2018, 155: 990-1003.e1. PMID: 30012334, DOI: 10.1053/j.gastro.2018.06.082.Peer-Reviewed Original ResearchConceptsIgG4-RDPlasma cellsExtra-intestinal manifestationsHuman IgG4-RDSimilar immune reactionsRelapsing-remitting courseDense lymphoplasmacytic infiltrateTiters of autoantibodiesMulti-organ diseasePermanent organ damageObliterative phlebitisStoriform fibrosisAutoimmune etiologyMetachronous lesionsPrimary therapyExcellent prognosisLymph nodesLymphoplasmacytic infiltrateSerum levelsOrgan damageSerum IgG4Bile ductAutoimmune diseasesTypical presentationInflammatory responseReply to ‘The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology’ by Kirova et al.
Dubsky P, Curigliano G, Burstein HJ, Winer EP, Gnant M, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn H, Thürlimann B, 2017 P, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang C, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B. Reply to ‘The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology’ by Kirova et al. Annals Of Oncology 2018, 29: 281-282. PMID: 29045519, PMCID: PMC6246427, DOI: 10.1093/annonc/mdx543.Peer-Reviewed Original Research
2017
Diet Quality, Inflammation, and Quality of Life in Breast Cancer Survivors: A Cross-Sectional Analysis of Pilot Study Data
Orchard T, Andridge R, Yee L, Lustberg M. Diet Quality, Inflammation, and Quality of Life in Breast Cancer Survivors: A Cross-Sectional Analysis of Pilot Study Data. Journal Of The Academy Of Nutrition And Dietetics 2017, 118: 578-588.e1. PMID: 29233615, PMCID: PMC5869134, DOI: 10.1016/j.jand.2017.09.024.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBreast NeoplasmsCancer SurvivorsCross-Sectional StudiesDietDrug-Related Side Effects and Adverse ReactionsFemaleHumansInflammationInterleukin-17Interleukin-6Middle AgedPilot ProjectsPostmenopauseQuality of LifeReceptors, Tumor Necrosis Factor, Type IITreatment OutcomeConceptsBreast cancer survivorsBody mass indexQuality of lifeLower IL-6Cancer survivorsDiet qualityIL-6Breast cancerTNFR-2QOL measuresEndocrine receptor-positive breast cancerReceptor-positive breast cancerEarly-stage breast cancerMidwestern cancer centerModifiable lifestyle factorsSerum proinflammatory cytokinesCancer Therapy-BreastHealthy Eating IndexAromatase inhibitor treatmentCross-sectional analysisEndocrine subscaleOverall HEIPrior chemotherapyPostmenopausal womenPrimary therapyDe-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn H, Thürlimann B, André F, Baselga J, Bergh J, Bonnefoi H, Brucker S, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes D, Huang C, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne K, Pagani O, Partridge A, Pritchard K, Ro J, Rutgers E, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan T, Xu B. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Annals Of Oncology 2017, 28: 1700-1712. PMID: 28838210, PMCID: PMC6246241, DOI: 10.1093/annonc/mdx308.Peer-Reviewed Original ResearchConceptsLow-risk patientsBreast cancerNeoadjuvant therapyPostmenopausal womenEarly-stage breast cancerER-positive breast cancerAvoidance of chemotherapyDe-escalate therapyAdjuvant endocrine treatmentRegional nodal irradiationHigh-risk patientsEarly breast cancerSentinel node biopsyHigh-risk tumorsPositive breast cancerBreast cancer recurrenceExpert consensus conferenceSubstantial new evidenceNodal irradiationBisphosphonate useEndocrine treatmentNeoadjuvant treatmentOvarian suppressionPremenopausal womenPrimary therapyThe Role of Endovascular In Situ Revascularization in the Treatment of Arterial and Graft Infections
Strosberg DS, Oriowo BA, Davies MG, Sayed H. The Role of Endovascular In Situ Revascularization in the Treatment of Arterial and Graft Infections. Annals Of Vascular Surgery 2017, 42: 299.e15-299.e20. PMID: 28279718, DOI: 10.1016/j.avsg.2016.10.044.Peer-Reviewed Original ResearchConceptsGraft infectionSitu revascularizationStent graftingStent graft coverageProsthetic graft infectionCarotid artery aneurysmArterial infectionBypass infectionExtraanatomical bypassMycotic aneurysmPrimary therapyAcute ruptureEndovascular repairIliac aneurysmsMycotic pseudoaneurysmTissue infectionsArtery aneurysmSignificant morbidityTraditional excisionInfectionAneurysmsExcisionRevascularizationInfected tissuesTreatment
2016
Disparities in Treatment of Patients With High-risk Prostate Cancer: Results From a Population-based Cohort
Wang E, Yu J, Abouassally R, Meropol N, Cooper G, Shah N, Williams S, Gonzalez C, Smaldone M, Kutikov A, Zhu H, Kim S. Disparities in Treatment of Patients With High-risk Prostate Cancer: Results From a Population-based Cohort. Urology 2016, 95: 88-94. PMID: 27318264, DOI: 10.1016/j.urology.2016.06.010.Peer-Reviewed Original ResearchConceptsHigh-risk prostate cancerWatchful waitingRadiation therapyProstate cancerPrimary treatmentTreatment of high-risk prostate cancerOdds ratioNational Cancer Data BaseMultivariate logistic regression analysisTreatment of patientsLogistic regression analysisRadical prostatectomyPrimary therapyCurative therapyPrimary outcomeCancer communityTherapySignificant racial disparitiesAcademic hospitalPatientsBlack menCancerHospitalStudy periodWhite men
2013
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn H, members P, Albain K, André F, Bergh J, Bonnefoi H, Bretel-Morales D, Burstein H, Cardoso F, Castiglione-Gertsch M, Coates A, Colleoni M, Costa A, Curigliano G, Davidson N, Di Leo A, Ejlertsen B, Forbes J, Gelber R, Gnant M, Goldhirsch A, Goodwin P, Goss P, Harris J, Hayes D, Hudis C, Ingle J, Jassem J, Jiang Z, Karlsson P, Loibl S, Morrow M, Namer M, Osborne C, Partridge A, Penault-Llorca F, Perou C, Piccart-Gebhart M, Pritchard K, Rutgers E, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Thürlimann B, Toi M, Tutt A, Untch M, Viale G, Watanabe T, Wilcken N, Winer E, Wood W. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals Of Oncology 2013, 24: 2206-2223. PMID: 23917950, PMCID: PMC3755334, DOI: 10.1093/annonc/mdt303.Peer-Reviewed Original ResearchConceptsEarly breast cancerLuminal diseaseBreast cancerHuman epidermal growth factor receptor 2 (HER2) oncogeneSt Gallen International Expert ConsensusBroad treatment recommendationsReproducible prognostic informationSystemic adjuvant therapyClinico-pathological factorsAnnals of OncologyMolecular assaysSubstantial new evidenceTreatment of womenInternational expert consensusPrimary therapyAdjuvant therapyExtensive surgeryDisease extentRegional therapyPatient preferencesPrognostic informationTreatment recommendationsChemotherapy decisionsRadiation therapyClinical considerations
2012
Toxicities and outcomes among septuagenarians and octogenarians with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy
Huntington SF, Talbott MS, Greer JP, Morgan DS, Reddy N. Toxicities and outcomes among septuagenarians and octogenarians with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy. Leukemia & Lymphoma 2012, 53: 1461-1468. PMID: 22260160, PMCID: PMC7845767, DOI: 10.3109/10428194.2012.658793.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsComorbidityCyclophosphamideDisease-Free SurvivalDoxorubicinFemaleGeriatricsHumansLymphoma, Large B-Cell, DiffuseMaleMedical OncologyMiddle AgedPrednisoneRemission InductionRetrospective StudiesRituximabTreatment OutcomeVincristineConceptsNon-Hodgkin lymphomaLarge cell lymphomaCell lymphomaDiffuse large B-cell lymphomaLarge B-cell lymphomaChemotherapy dose reductionsTreatment-related toxicityR-CHOP treatmentSingle-institution studyB-cell lymphomaCurative intentRelative chemotherapyComplete remissionPrimary therapyElderly patientsSupportive careTreatment toxicityAged patientsPatient populationTreatment outcomesRetrospective analysisDose reductionElderly populationPatientsLymphoma
2010
Treatment of Acute Bleeding
Laine L, Abid S, Albillos A, Kamath P, Vinel J, García‐Pagán J. Treatment of Acute Bleeding. 2010, 101-118. DOI: 10.1002/9781444393989.ch10.ChaptersTissue-Engineered Lungs for in Vivo Implantation
Petersen TH, Calle EA, Zhao L, Lee EJ, Gui L, Raredon MB, Gavrilov K, Yi T, Zhuang ZW, Breuer C, Herzog E, Niklason LE. Tissue-Engineered Lungs for in Vivo Implantation. Science 2010, 329: 538-541. PMID: 20576850, PMCID: PMC3640463, DOI: 10.1126/science.1189345.Peer-Reviewed Original ResearchConceptsLung tissueLung matrixAcellular lung matrixNative lung tissueTissue-engineered lungsLung transplantationPrimary therapyAdult lung tissueAdult ratsPulmonary epitheliumVascular endotheliumFunctional lungLung regenerationVascular compartmentLungSeeded endothelial cellsMechanical characteristicsEndothelial cellsVivo implantationRatsEpitheliumTissueCellular componentsExtracellular matrixGas exchangeOutcomes following local therapy for early-stage breast cancer in non-trial populations
Keating NL, Landrum MB, Brooks JM, Chrischilles EA, Winer EP, Wright K, Volya R. Outcomes following local therapy for early-stage breast cancer in non-trial populations. Breast Cancer Research And Treatment 2010, 125: 803-813. PMID: 20376555, PMCID: PMC2924956, DOI: 10.1007/s10549-010-0865-4.Peer-Reviewed Original ResearchConceptsBreast-conserving surgeryEarly-stage breast cancerClinical trialsBreast cancerEarly-stage breast cancer patientsPrimary breast cancer therapyPrimary breast cancer treatmentEnd Results cancer registryNon-trial populationBreast cancer patientsPopulation-based dataBreast cancer treatmentBreast cancer therapyNon-selected populationPropensity score analysisMedicare administrative dataMore mastectomiesPrimary therapyLocal therapySurveillance EpidemiologyAdjusted survivalCancer RegistryCancer patientsHospital characteristicsMastectomy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply